Shares of Novartis were climbing higher on Friday after the Food and Drug Administration (FDA) approved Novartis’ $2.1 million gene therapy Zolgensma. Zolgensma is a one-time treatment for spinal muscular atrophy and is the world’s most expensive drug now. Previously Novartis had said that the treatment could cost anywhere from $1.5 to $5 million but … Continue reading “Novartis’ Gene Therapy Gets Nod from FDA”
Tag: Vas Narasimhan
Biotech & Pharma
Novartis Just Made an $8.7 Billion Dollar Bet on this Gene Therapy Company
Novartis and AveXis shares saw big gains in Monday trading after it was announced that…
April 9, 2018